Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for WUXAY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for WUXAY and 80,000+ other tickers.
See exactly how WUXAY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for WUXAY and 80,000+ other tickers.
WuXi AppTec Co., Ltd. functions as an investment holding entity, globally delivering a wide array of research, development, and manufacturing services. Operating across the People's Republic of China, other parts of Asia, the United States, and Europe, the company plays a crucial role in the discovery, advancement, and production of small molecule pharmaceuticals, as well as cell and gene therapies. The organization's operations are divided into six main segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Additional Services. It provides extensive contract research…
Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.
Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.
WuXi AppTec said on Thursday that it has filed a complaint at the United States District Court for the District of Columbia against the Department of Defense for including the company in a list linked to the Chinese military.
SHANGHAI, May 17, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Index, formerly Dow Jones Sustainability World Index), which recognizes the top-performing companies in each industry on long-term sustainability criteria. This recognition reflects progress that WuXi AppTec has made in integrating responsible sustainability practices across its operations and strategies.
WuXi AppTec Co., Ltd. (OTCMKTS:WUXAY - Get Free Report) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 1,622 shares, a growth of 76.7% from the March 31st total of 918 shares. Based on an average trading volume of 824 shares, the short-interest